OREANDA-NEWS. Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on January 21 - 24, 2015, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab World. Serving as a WEF Regional Associate for the second consecutive year, Hikma was one of 2,540 business, government, academic and civil society leaders to convene this year to explore solutions for pressing international, regional and industry issues within 'The New Global Context' - the Forum's theme - as brought on by breakthrough technologies, demographic shifts and political transformations.

Representing Hikma, Mazen Darwazeh, Vice Chairman, President and CEO of MENA and Emerging Markets, participated as a discussion leader in the 'Arab World Growth Markets' session alongside Jordan's Minister of Finance, Umayya Toukan; the Palestinian National Authority's Deputy Prime Minister and Minister of Economy, Mohammad Mustafa; and Dana Gas PJSC's CEO, Patrick Allman-Ward. During the session, Darwazah elaborated on the economic consequences of falling oil prices; the potential of cross-sector and public-private integration; as well as the need for greater investment in, and Hikma's contribution to, talent and education development. 

"Public-private and international cooperation is key to ensuring the sustainable growth of worldwide economies in the face of significant oil price shocks, geopolitical tensions and the persistent gap in scientific, technical and human skills," said Darwazeh. "As a rapidly-growing multinational group with markets in more than 50 countries, Hikma is committed to helping communities boost their resilience and adaptability to societal, political and commercial changes, a vision that is reflected in our partnership with the WEF." 

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In December 2013, Hikma had 7,067 employees worldwide.